

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Liebmann-Vinson et al.

SERIAL NO.: 10/660,760

GROUP:

1712

FILING DATE:

September 12, 2003

EXAMINER:

FOR:

METHODS OF SURFACE MODIFICATION OF A FLEXIBLE

SUBSTRATE TO ENHANCE CELL ADHESION

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

> INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 53(d) CPA APPLICATION OR WITH A RULE 1.114 RCE APPLICATION)

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO/SB/08A(s), attached hereto.

II. <u>COPIES</u> (check at least one box)

- a. Submitted herewith is a legible copy of (i) each foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. Some or all of the documents listed on the PTO/SB/08A are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

consideration.

The following additional information is provided for the Examiner's

B

<u>FEES</u>

IV.	\boxtimes		IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b): k one box)
	a.		within three months of the filing date of a national application (37 C.F.R § 1.97(b)(1)). No fee or statement is required. (This section is not to be used with RCE's and CPA's).
	b.		within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee of statement is required.
	c.		concurrently with the filing of a Continued Prosecution Application under 37 C.F.R. § 1.53(d) or concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
	d.		before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required.
			In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has been made, charge Deposit Account No. 02-1666 in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
V.			IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): k one box)
	1.97(c	c)(1)) or	ailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 R. § 1.97(c)(2)).
	a.		No statement; therefore, a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).
			or
	b.		See the statement below. No fee is required.

STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) The undersigned hereby states that a. each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or b. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. Some of the items of information were cited in a communication from a c. foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. VII. PAYMENT OF FEES (check one box) A check in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p) is enclosed for the above-identified fee. No fee is required. M Please charge Deposit Account No. 02-1666 in the amount required by 37 C.F.R. § 1.17(p) for the above-indicated fee. A triplicate copy of this paper is attached.

VI.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-1666.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future

replies, to charge payment or credit any overpayment to Deposit Account No. 02-1666 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees. Respectfully submitted, Becton, Dickinson and Company Date: February 23,2 1 Becton Drive, MC 089 Franklin Lakes, New Jersey 07417 (201) 847-6659 Enclosures: ▼ PTO/SB/08A Documents Foreign Search Report Fee Other: (Rev. 01/03/03 I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA Doc. No. 74881

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper of Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute to form 1449/PTO

FEB 2 6 2004

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Col	mplete if Known	
Application Number	10/660,760	
Filing Date	September 12, 2003	
First Named Inventor	LIEBMANN-VINSON et al	
Art Unit		
Examiner Name		
Attorney Docket Number	P-5838	

			U. S. PATENT	DOCUMENTS		
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear	
		Number-Kind Code ^{2 (# known)}	05.00.000	B	- Igaico / Appedi	
		^{US-} 6395506	05-28-2002	Pitner et al.		
		^{US-} 6218178	04-17-2001	Banes		
		^{US-} 6107083	08-22-2000	Collins et al.		
		^{US-} 6080574	06-27-2000	Berndt		
		^{US-} 6057150	05-02-2000	Lee et al.		
		^{US-} 6048723	04-11-2000	Banes		
		^{US-} 6037141	03-14-2000	Banes		
		^{US-} 5998517	12-07-1999	Gentle et al.		
		^{US-} 5567598	10-22-1996	Stitt et al.		
		^{US-} 5278063	01-11-1994	Hubbell et al		
		^{US-} 4851521	07-25-1989	della Valle et al		
		^{US-} 4839280	06-13-1989	Banes		
		^{US-} 4822741	04-18-1989	Banes		
		^{US-} 4789601	12-06-1988	Banes		
		US-				
		US-				
		US-				
		US-				
	-	US-				

		FOREI	GN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶

Examiner	Date	
Signature	Considered	
- 5		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (04-03)

FEB 2 6 2004 Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE iction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 14 **Application Number** 10/660,760 INFORMATION DISCLOSURE **Filing Date** September 12, 2003 STATEMENT BY APPLICANT **First Named Inventor** LIEBMANN-VINSON et al Art Unit (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number Sheet 2 P-5838 5 of

Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of			NON PATENT LITERATURE DOCUMENTS	
CHAUDHURY et al., Langmuir, (1991) 7:1013-1025. CHOI et al., Biomaterials (1999) 20:409-417. COSTELLO et al., Macromolecules (1987) 20:2819-2828. COUCHMAN et al., J.Cell Biol., (1982) 93:402-410. EFIMENKO et al., J. Colloid Interface Sci., (2002) 254(2):306-315. EFIMENKO et al., Adv. Matl., (2001) 13:1560-63. GENZER et al., Science (2000) 290:2130-33. GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.		1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
CHOI et al., Biomaterials (1999) 20:409-417. COSTELLO et al., Macromolecules (1987) 20:2819-2828. COUCHMAN et al., J.Cell Biol.,(1982) 93:402-410. EFIMENKO et al., J. Colloid Interface Sci., (2002) 254(2):306-315. EFIMENKO et al., Adv. Matl., (2001) 13:1560-63. GENZER et al., Science (2000) 290:2130-33. GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.			BRANDLEY et al., Anal. Biochem. (1988) 172:270.	
COSTELLO et al., Macromolecules (1987) 20:2819-2828. COUCHMAN et al., J.Cell Biol.,(1982) 93:402-410. EFIMENKO et al., J. Colloid Interface Sci., (2002) 254(2):306-315. EFIMENKO et al., Adv. Matl., (2001) 13:1560-63. GENZER et al., Science (2000) 290:2130-33. GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.			CHAUDHURY et al., Langmuir, (1991) 7:1013-1025.	
COUCHMAN et al., J. Cell Biol.,(1982) 93:402-410. EFIMENKO et al., J. Colloid Interface Sci., (2002) 254(2):306-315. EFIMENKO et al., Adv. Matl., (2001) 13:1560-63. GENZER et al., Science (2000) 290:2130-33. GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.			CHOI et al., Biomaterials (1999) 20:409-417.	
EFIMENKO et al., J. Colloid Interface Sci., (2002) 254(2):306-315. EFIMENKO et al., Adv. Matl., (2001) 13:1560-63. GENZER et al., Science (2000) 290:2130-33. GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.			COSTELLO et al., Macromolecules (1987) 20:2819-2828.	
EFIMENKO et al., Adv. Matl., (2001) 13:1560-63. GENZER et al., Science (2000) 290:2130-33. GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.			COUCHMAN et al., J.Cell Biol.,(1982) 93:402-410.	
GENZER et al., Science (2000) 290:2130-33. GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.			EFIMENKO et al., J. Colloid Interface Sci., (2002) 254(2):306-315.	
GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.			EFIMENKO et al., Adv. Matl., (2001) 13:1560-63.	
			GENZER et al., Science (2000) 290:2130-33.	
GUTSCHE et al., Biomaterials (1996) 17:387-393.			GRINNELL, F., Int. Rev. Cytology (1978) 53:67-149.	
	-		GUTSCHE et al., Biomaterials (1996) 17:387-393.	

Examiner	Date
Signature	Considered
	· · · · · · · · · · · · · · · · · · ·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

FEB 2 6 2004 Lander the Paperwork Reduction

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

aduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Company (PTO		Complete if Known
Substitute 1970	Application Number	10/660,760
INFORMATION DISCLOSURE	Filing Date	September 12, 2003
STATEMENT BY APPLICANT	First Named Inventor	LIEBMANN-VINSON et al
	Art Unit	
(Use as many sheets as necessary)	Examiner Name	
Sheet 3 of 5	Attorney Docket Number	P-5838

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-iss number(s), publisher, city and/or country where published.					
		HERN et al., J. Biomed. Mater. Res. (1998) 39:266-276.				
		HSIUE et al., J. Biomed. Mater. Res., (1998) 42:134-147.				
		KIM et al., Ann. Surgery (1998) 228:8-13.				
		KLEINMAN, et al., Biochem. Biophys. Res. Commun. (1976) 72:426-432.				
		LATEEF et al., Biomaterials, (2002) 23: 3159-3168.				
		LEE et al., Journal of Polymer Science: Part A: Polymer Chemistry, (1996) 34:141-148.				
		LU et al., Biomaterials (2000) 21: 1595- 1605.				
		MADIHALLY et al., Biomaterials. (1999) 20:1133-42				
		MOONEY et al., Biomaterials (1996) 17:1417-1422.				
		MURAKAMI et al., J. Colloid & Interface Science (1998) 200:192-94.				

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

FEB 2 6 2004

PTO/SB/08B (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

duction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e 10/10/11/14/19/PTO				Complete if Known
Cabsinal	C 101 10411 10			Application Number	10/660,760
INFO	DRMATION	I DIS	CLOSURE	Filing Date	September 12, 2003
STATEMENT BY APPLICANT				First Named Inventor	LIEBMANN-VINSON et al
	(1100 00 00000 000	4		Art Unit	
	(Use as many she	ets as n	ecessary)	Examiner Name	
Sheet	4	of	5	Attorney Docket Number	P-5838

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		OXLEY et al. Biomaterials (1993) 14:1064-1072.	
		PEARLSTEIN, E., Nature (1976) 262:497-500.	
		PINILLA et al., Meth. Molec. Biol., (1996) 66:171-179.	
		RANUCCI et al., Tissue Engineering (1999) 5: 407-420.	
		SAAD et al., J. Biomed. Res. (1996) 32:355-366.	
		SILVER et al., Biomaterials, (1999) 20: 1533-1543.	
		SILVER et al., Journal of Biomedical Materials Research (1995) 29:535-548.	
		SINGER et al., J. Cell Biol. (1987) 104:573-584.	
		TORRES et al., Biomaterials (2000) 21:1607-19.	
		VOGLER et al., Journal of Biomedical Materials Research (1987) 21:1197-1211.	

Eveminer	Date	
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (04-03) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

7 . . .			ct of 1995, no persons ar	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitut	ACEMA			Application Number	10/660,760		
INFORMATION DISCLOSURE				Filing Date	September 12, 2003		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	LIEBMANN-VINSON et al		
(Use as many sheets as necessary)				Art Unit			
	(USB as many sne	ets as n	ecessary)	Examiner Name			
Sheet	5	of	5	Attorney Docket Number	P-5838		

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	WHANG et al., Polymer (1995) 36:837-842.	
	WU et al., Macromolecules (2001) 34:684-86.	
	ZHANG et al., J. Biomed. Mater. Res., (1999) 45:285-293.	
	Cite No.1	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. WHANG et al., Polymer (1995) 36:837-842. WU et al., Macromolecules (2001) 34:684-86.

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.